argenx announces approval of VYVDURA in Japan for CIDP
- Japan's Ministry of Health, Labour and Welfare approved VYVDURA for chronic inflammatory demyelinating polyneuropathy (CIDP).
- VYVDURA is a once-weekly subcutaneous injection for at-home use, the first FcRn blocker approved for CIDP.
- Approval based on the ADHERE trial, showing 69% of patients improved with VYVDURA, reducing relapse risk by 61%.
- VYVDURA was previously approved for generalized myasthenia gravis and designated as an Orphan Drug for CIDP in Japan.
Read more
